Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01823341 · ClinicalTrials.gov registry record · Phase 2

Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children

A Phase 2 study, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 2
Development phase
97
Enrollment target

NCT01823341: Completed Phase 2 study, sponsored by Jaeb Center for Health Research.

NCT01823341 is a Phase 2 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 97 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01823341, a Phase 2 study, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 2
Development phase
97 participants
Enrollment target

Study Summary

The purpose of this study is to see whether low blood sugar at night can be reduced by using a system that turns off the insulin pump automatically. The study system includes a continuous glucose monitor (CGM) and an insulin pump. The CGM and pump work with a regular laptop computer. A The system works by (1) measuring the glucose levels under the skin with the CGM, (2) using a computer program on the laptop to predict whether a low blood sugar is likely to occur, and (3) turning off the insulin pump when the computer program predicts that a low blood sugar will occur. We have tested the system in the home environment in individuals with type 1 diabetes age 15 years and older. We have found an indication that the system can decrease the frequency of hypoglycemia. We have not had any serious cases of high blood sugars or other problems. We are now ready to further test the system in the home environment in a younger age group to learn more about its ability to reduce overnight low blood sugar risk. This study has several phases and will take about 3 months for a patient to complete. * First, the patient will use the CGM and pump at home for up to 15 days with the help of a parent/guardian. This is done to determine if the patient meets our study criteria to proceed with the next phase of the study. * If the patient is eligible to continue in the study, the patient will need to use the full study system for at least 5 nights at home with the help of a parent/guardian. This is done to make sure the patient and parent/guardian are able to use the system correctly. The patient may participate in starting and stopping the system at home, but the parent/guardian is responsible for making sure it is used as instructed. * After that, the patient will be asked to use the study system each night for an additional 6 to 8 weeks. The parent/guardian will remain responsible for making sure the system is used as instructed. The study will include about 90 individuals with type

Primary Outcome

Each night is categorized as to whether hypoglycemia occurred. Hypoglycemia is defined as the occurrence of one or more CGM glucose values ≤70 mg/dL (3.9 mmol/L). The time period for outcome assessment each night will be from the time the system is activated in the evening until the time it is deactivated in the morning. The percentage of hypoglycemic nights (CGM glucose value ≤70 mg/dL (3.9 mmol/L)) will be tabulated separately with versus without the closed-loop control system in use. We consi

Interventions

  • DEVICE Pump suspension algorithm

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2013-05
Est. Completion 2014-09
Phase Phase 2
Jaeb Center for Health Research

119 total trials

What the finished NCT01823341 record still lists

NCT01823341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% lower).

The record links to 0 conditions, and to 1 intervention - of which Pump suspension algorithm is the first listed.

NCT01823341 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01823341 about?

NCT01823341 is a clinical study titled "Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children". The purpose of this study is to see whether low blood sugar at night can be reduced by using a system that turns off the insulin pump automatically. The study system includes a continuous glucose monitor (CGM) and an insulin pump. The CGM and pump work with a regular laptop computer. A The system wo...

What is the current status of trial NCT01823341?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2013-05. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01823341?

The interventions under investigation include: Pump suspension algorithm (DEVICE).

Who is sponsoring clinical trial NCT01823341?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01823341's enrollment target sits among peer trials

97 746th of 2000 higher than 1,254 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03948490 · 97 participants · NA

    Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

  • NCT04140487 · 97 participants · Phase 1

    Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

  • NCT04196413 · 97 participants · Phase 1

    GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

  • NCT05223816 · 97 participants · Phase 2

    An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01823341, the US trial registry maintained by the National Library of Medicine. NCT01823341 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.